 Home > Medical News > Medicines Company News > Tianxing Pharmaceutical will announce its clinical data of ADG116, an anti-CTLA-4 new epitope antibody, in poster form at the 2022 SITC Annual Meeting

Tianxing Pharmaceutical will announce its clinical data of ADG116, an anti-CTLA-4 new epitope antibody, in poster form at the 2022 SITC Annual Meeting

 Last Update: 2022-10-31
 Source: Internet
 Author: User

Tags

lfa 1 24

anti gm1 antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Tianxing Pharmaceuticals (the "Company" or "Tianxing") (NASDAQ: ADAG) is a platform-driven clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer immunotherapies
based on original antibodies.
The Company announced on October 11 that it will present data
from its Phase II/II trial of NEObody™ADG116 Ib/II, an anti-CTLA-4 neoepitope antibody, at the 37th Annual Meeting of the American Society for Immunotherapy for Cancer (SITC), to be held in Boston from November 8 to 12, 2022.

The poster will disclose: compelling safety data on ADG116 in monotherapy and in combination with two different anti-PD-1 therapies and repeated dosing; and the antitumor activity observed with ADG116 in patients with hot and cold tumors, including partial remission observed in one patient with monotherapy and confirmed complete remission
in one patient with combination therapy and repeated dosing for tumor types for which existing anti-CTLA-4 therapies have not been approved.

The poster details are as follows:

: Phase 1b/2 study of anti-CTLA-4 neoepitope antibody NEObody™ADG116 monotherapy and combination with trepilimab in patients with advanced/metastatic solid tumors

Display date: Thursday, November 10, 2022 (abstract release date, November 7)

Hours: 9:00 a.
m.
to 9:00 p.
m.
ET, 10:00 p.
m.
to 10:00 a.
m.
Beijing time

Exhibition location (on-site participants): Poster hall

Abstract number: 753

: Preliminary update on the Phase 1b/2 open-label, dose escalation and expansion study of the anti-CTLA-4 neoepitope antibody NEObody™ADG116 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

Display date: Thursday, November 10, 2022 (abstract release date, November 7)

Exhibition time: 9:00 a.
m.
– 9:00 p.
m.
EST, that is, 10:00 p.
m.
to 10:00 a.
m.
Beijing time

Exhibition location (on-site participants): Poster hall

Abstract number: 773

At that time, you can visit the publication page of the company's official website to view the relevant posters
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.